Peter Johnson

2.7k total citations
44 papers, 1.2k citations indexed

About

Peter Johnson is a scholar working on Hematology, Oncology and Genetics. According to data from OpenAlex, Peter Johnson has authored 44 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Hematology, 12 papers in Oncology and 10 papers in Genetics. Recurrent topics in Peter Johnson's work include Acute Myeloid Leukemia Research (16 papers), Acute Lymphoblastic Leukemia research (9 papers) and Multiple Myeloma Research and Treatments (7 papers). Peter Johnson is often cited by papers focused on Acute Myeloid Leukemia Research (16 papers), Acute Lymphoblastic Leukemia research (9 papers) and Multiple Myeloma Research and Treatments (7 papers). Peter Johnson collaborates with scholars based in United Kingdom, United States and Italy. Peter Johnson's co-authors include J. A. Liu Yin, John A. Liu Yin, J A Tooth, Christine J. Harrison, Nigel H. Russell, Khalid Tobal, Donna L. Forrest, Tessa L. Holyoake, Clayton A. Smith and Tim Lister and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Peter Johnson

42 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peter Johnson United Kingdom 18 720 358 321 235 182 44 1.2k
Arno Enno Australia 13 501 0.7× 279 0.8× 298 0.9× 224 1.0× 245 1.3× 24 967
J. A. Liu Yin United Kingdom 21 940 1.3× 372 1.0× 292 0.9× 223 0.9× 328 1.8× 42 1.2k
Marianna Criscuolo Italy 21 481 0.7× 295 0.8× 194 0.6× 233 1.0× 92 0.5× 72 1.0k
A Iriondo Spain 19 625 0.9× 166 0.5× 255 0.8× 130 0.6× 190 1.0× 45 1.0k
Taiichi Kyo Japan 24 855 1.2× 549 1.5× 256 0.8× 368 1.6× 304 1.7× 64 1.6k
Concetta Micalizzi Italy 22 593 0.8× 331 0.9× 214 0.7× 133 0.6× 347 1.9× 81 1.2k
J Cahn France 22 1.2k 1.6× 282 0.8× 392 1.2× 216 0.9× 364 2.0× 70 1.6k
Walter Feremans Belgium 16 601 0.8× 177 0.5× 178 0.6× 338 1.4× 142 0.8× 58 981
Xavier Poiré Belgium 17 505 0.7× 197 0.6× 401 1.2× 115 0.5× 184 1.0× 69 971
Bernardino Allione Italy 14 631 0.9× 375 1.0× 837 2.6× 150 0.6× 89 0.5× 39 1.4k

Countries citing papers authored by Peter Johnson

Since Specialization
Citations

This map shows the geographic impact of Peter Johnson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Johnson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Johnson more than expected).

Fields of papers citing papers by Peter Johnson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Johnson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Johnson. The network helps show where Peter Johnson may publish in the future.

Co-authorship network of co-authors of Peter Johnson

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Johnson. A scholar is included among the top collaborators of Peter Johnson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Johnson. Peter Johnson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Viviani, Simonetta, Chiara Pavoni, Sally F. Barrington, et al.. (2025). Advanced stage classical Hodgkin lymphoma patients with a positive interim-PET (PET-2) Deauville score 5 after 2 ABVD cycles: a pooled analysis of three multicenter trials. Blood Cancer Journal. 15(1). 165–165.
2.
Johnson, Peter, et al.. (2018). Management of Persistent Hyponatremia Induced by Long-acting Injectable Risperidone Therapy. Cureus. 10(5). e2657–e2657. 1 indexed citations
3.
4.
Dennis, Michael, Dominic Culligan, Dimitris Karamitros, et al.. (2013). Lenalidomide monotherapy and in combination with cytarabine, daunorubicin and etoposide for high-risk myelodysplasia and acute myeloid leukaemia with chromosome 5 abnormalities. Leukemia Research Reports. 2(2). 70–74. 7 indexed citations
5.
Owen, Carolyn, Cynthia L. Toze, Donna L. Forrest, et al.. (2008). Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy. Blood. 112(12). 4639–4645. 168 indexed citations
6.
7.
Dasgupta, Ranjit, Simon Rule, Peter Johnson, et al.. (2006). Fludarabine phosphate and melphalan: a reduced intensity conditioning regimen suitable for allogeneic transplantation that maintains the graft versus malignancy effect. Bone Marrow Transplantation. 37(5). 455–461. 16 indexed citations
8.
Jordanides, Niove E., Elaine Allan, Lorna McLintock, et al.. (2005). A prospective study of real-time panfungal PCR for the early diagnosis of invasive fungal infection in haemato-oncology patients. Bone Marrow Transplantation. 35(4). 389–395. 81 indexed citations
9.
Johnson, Peter, et al.. (2001). Trisomy 14 in myeloid malignancies. Cancer Genetics and Cytogenetics. 124(2). 172–174. 9 indexed citations
10.
Johnson, Peter, et al.. (2000). Eradication of a resistant Pseudomonas aeruginosa strain after a cluster of infections in a hematology/oncology unit. Clinical Microbiology and Infection. 6(3). 125–130. 43 indexed citations
11.
Roddie, P. H., D A Collie, & Peter Johnson. (2000). Myelomatous involvement of the dura mater: a rare complication of multiple myeloma: Figure 1. Journal of Clinical Pathology. 53(5). 398–399. 27 indexed citations
12.
Johnson, Peter & John A. Liu Yin. (1997). THE ROLE OF GRANULOCYTE‐ AND GRANULOCYTE‐MACROPHAGE‐COLONY‐STIMULATING FACTORS IN THE TREATMENT OF ACUTE MYELOID LEUKAEMIA. British Journal of Haematology. 97(1). 1–8. 7 indexed citations
13.
Tobal, Khalid, et al.. (1995). Detection of CBFB/MYH11 transcripts in patients with inversion and other abnormalities of chromosome 16 at presentation and remission. British Journal of Haematology. 91(1). 104–108. 70 indexed citations
14.
Johnson, Peter & John A. Liu Yin. (1994). Prognostic Factors in Elderly Patients with Acute Myeloid Leukaemia. Leukemia & lymphoma. 16(1-2). 51–56. 15 indexed citations
15.
Johnson, Peter & J. A. Liu Yin. (1993). ACUTE MYELOID LEUKAEMIA IN THE ELDERLY: BIOLOGY AND TREATMENT. British Journal of Haematology. 83(1). 1–6. 46 indexed citations
16.
Johnson, Peter, et al.. (1992). A randomized trial of high-dose ciprofloxacin versus azlocillin and netilmicin in the empirical therapy of febrile neutropenic patients. Journal of Antimicrobial Chemotherapy. 30(2). 203–214. 28 indexed citations
17.
Johnson, Peter, J. A. Liu Yin, Manikandan Narayanan, et al.. (1991). Failure of mithramycin to control the myeloid blast phase of chronic granulocytic leukemia: A report on nine patients and review of the literature. Hematological Oncology. 9(1). 9–15. 6 indexed citations
18.
Harrison, Christine J., Peter Johnson, J. A. Liu Yin, & M. Bhavnani. (1991). Alveolar rhabdomyosarcoma with del(13q14). Cancer Genetics and Cytogenetics. 55(2). 257–259. 6 indexed citations
19.
Fitzmaurice, Richard J., Peter Johnson, J. A. Liu Yin, & Anthony J. Freemont. (1991). Rhabdomyosarcoma presenting as ‘acute leukaemia’. Histopathology. 18(2). 173–175. 10 indexed citations
20.
Yin, J. A. Liu, et al.. (1991). Mitozantrone and cytosine arabinoside as first‐line therapy in elderly patients with acute myeloid leukaemia. British Journal of Haematology. 79(3). 415–420. 61 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Arno Enno Breakdown of academic impact, for papers by J. A. Liu Yin Breakdown of academic impact, for papers by Marianna Criscuolo Breakdown of academic impact, for papers by A Iriondo Breakdown of academic impact, for papers by Taiichi Kyo Breakdown of academic impact, for papers by Concetta Micalizzi Breakdown of academic impact, for papers by J Cahn Breakdown of academic impact, for papers by Walter Feremans Breakdown of academic impact, for papers by Xavier Poiré Breakdown of academic impact, for papers by Bernardino Allione
Rankless by CCL
2026